Skip to main content

Journals in Immunology

1-10 of 87 results in All results

Acta Tropica

  • ISSN: 0001-706X
  • 5 Year impact factor: 2.7
  • Impact factor: 2.7
Acta Tropica, is an international journal on infectious diseases that covers public health sciences and biomedical research with particular emphasis on topics relevant to human and animal health in the tropics and the subtropics. Its scope includes the biology of pathogens and vectors, host-parasite relationships, mechanisms of pathogenicity, clinical disease and treatment, and we welcome contributions in basic or applied research in disciplines such as epidemiology, disease ecology, diagnostics, interventions and control, mathematical modeling, public health and social sciences, climate change, parasite and vector taxonomy, host and parasite genomics, biochemistry and immunology and vaccine testing. Contributions may be in the form of original research papers, review articles, short communications, opinion articles, or letters to the Editors. Only manuscripts of high scientific significance and innovation will be considered for publication. Manuscripts of minimal international relevance, case reports, and control strategies at very early inconclusive laboratory stages of development will not be considered for publication. Important Guidelines for Acceptance Editors and the Editorial Board of Acta Tropica provide the following guidelines to help authors prepare manuscripts of high quality that can be considered for publication. Maximize your chances of acceptance by making sure your manuscript: Matches the scientific scope of the journal, Presents results that significantly advance science including innovative new approaches, Meets quality standards of presentation and literature citation, Demonstrates potential health or biomedical impact. The above points are critical for publication of original papers. Be aware Editors carefully evaluate initial manuscript submissions and only those meeting the above criteria will be forwarded to review. If reviewed favorably and the authors seriously address all concerns, than chances of acceptance are increased. Review papers, in addition, are expected to carefully synthesize the literarture and make recommendations to advance respective scientific fields. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center
Acta Tropica

American Journal of Preventive Medicine

  • ISSN: 0749-3797
  • 5 Year impact factor: 5.9
  • Impact factor: 5.5
A Journal of the American College of Preventive Medicine and the Association for Prevention Teaching and Research The American Journal of Preventive Medicine is the official journal of the American College of Preventive Medicine and the Association for Prevention Teaching and Research. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. Of particular emphasis are papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and substance use disorders. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. Papers on health services research pertinent to prevention and public health are also published. The journal also publishes official policy statements from the two co-sponsoring organizations, review articles, media reviews, and editorials. Finally, the journal periodically publishes supplements and special theme issues devoted to areas of current interest to the prevention community. For information on the American College of Preventive Medicine (ACPM) and the Association for Prevention Teaching and Research (APTR), visit their web sites at the following URLs: http://www.acpm.org/ and http://www.aptrweb.org
American Journal of Preventive Medicine

Antiviral Research

  • ISSN: 0166-3542
  • 5 Year impact factor: 5.8
  • Impact factor: 7.6
A journal for research on the prevention and treatment of viral diseasesAn Official Publication of the International Society for Antiviral Research Antiviral Research publishes research reports, short communications, review articles and commentaries on the control of viral infections in humans and animals. Its scope encompasses: antiviral drugs, antibodies and host-response modifiers, including their synthesis, in vitro and in vivo testing and mechanisms of action. new or improved vaccines against viral infections of humans; assessments of drug and vaccine safety; evolution of drug- or vaccine-resistant viruses and the development of effective countermeasures; identification and validation of new drug targets; laboratory animal models of viral diseases; pathogenesis of viral diseases and mechanisms of viral evasion of host immune responses. We encourage the submission of manuscripts describing the activity of well-defined chemical compounds for the treatment of viral diseases of humans and vertebrate animals. We also publish manuscripts on the protective activity of vaccines for humans, and we will consider reports of the testing of veterinary vaccines in the target animal species. All papers must include a sufficiently detailed description of methods to permit other investigators to replicate the experiments. Authors reporting the antiviral effect of a novel small-molecule drug must reveal its chemical structure. Claims of in vitro or in vivo efficacy of a drug or vaccine must be supported by appropriate statistical analysis. Note: Antiviral Research may choose not to publish certain COVID-19 papers. The COVID-19 pandemic has focused attention on the possibility that patients infected with SARS-CoV-2 might benefit from treatment with certain licensed drugs approved for conditions other than viral infection. Reports that various medications inhibit the replication of the virus in vitro have been widely publicized in news articles and on medical websites, giving the impression that compounds still in the earliest stage of evaluation may be used to prevent or treat COVID-19. Such misunderstanding may result in the inappropriate use of a drug by physicians and to self-treatment by people who obtain it from other sources, with a risk of toxicity. This may be a particular problem when a medication is available without prescription as a veterinary product. Hoarding or inappropriate use of a drug intended to treat another disease may also make it unavailable to patients with that disease. The editors of Antiviral Research may therefore choose not to publish certain COVID-19 manuscripts, when in our judgment publication is likely to result in harm, without clear evidence of benefit. The scope of AVR also includes the prevention and treatment of viral diseases of vertebrate animals. We do not publish reports on viral diseases of plants or of insects, crustaceans or other invertebrates. Studies of viral diseases of livestock and companion animals must be clearly related to the development of realistic therapies. Papers on veterinary vaccines should report findings in the target animal species. We discourage the submission of manuscripts reporting the antiviral activity of unpurified natural products, or of partially purified substances of natural origin for which a mechanism of action has not been determined. Manuscripts claiming an antiviral effect of homeopathic products or other highly diluted preparations, or which fail to clearly identify the biological ingredient or molecule responsible for the antiviral activity of an experimental therapy, will not be considered for publication. Articles describing antiseptics with broad-spectrum antimicrobial activity will not be accepted. We also discourage submission of in silico docking studies or other computer-based predictions of antiviral activity that are not supported by data from biological assays. Citations of reports that have not undergone peer review must include the note "[not peer-reviewed]." Antiviral Research is an official publication of the International Society for Antiviral Research (http://www.isar-icar.com). Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center
Antiviral Research

Autoimmunity Reviews

  • ISSN: 1568-9972
  • 5 Year impact factor: 10.2
  • Impact factor: 13.6
Autoimmunity Reviews will publish up-to-date, structured reviews on diverse topics in autoimmunity, written by first-class experts in the field. The articles will include demonstrative illustrations and tables and will all have a "take-home" message. Articles will principally be invited by the Editors-in-Chief upon the recommendations of the international Editorial Board, and will cover all fields of autoimmunology, bridging the gap between basic and clinical sciences. Contributions in basic sciences will include those on the pathophysiology and mechanisms of disorders as well as genomics and proteomics; clinical contributions will focus upon the diseases, novel therapies and clinical associations. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center
Autoimmunity Reviews

Biochimica et Biophysica Acta: Molecular Basis of Disease

  • ISSN: 0925-4439
  • 5 Year impact factor: 6.2
  • Impact factor: 6.2
BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. Given the complex regulation of gene expression by a vast network of miRNA's, manuscripts describing the regulation of (disease-associated) genes by single miRNAs will only be considered if they provide genuine, novel insight in a disease mechanism. Further, studies restricted to a single cell line will not be considered unless they present truly novel insights. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center
Biochimica et Biophysica Acta: Molecular Basis of Disease

Biologicals

  • ISSN: 1045-1056
  • 5 Year impact factor: 1.6
  • Impact factor: 1.7
Journal of the International Alliance for Biological Standardization Biologicals provides a modern and multidisciplinary international forum for news, debate, and original research on all aspects of biologicals used in human and veterinary medicine. The journal publishes original papers, reviews, and letters relevant to the development, production, quality control, and standardization of biological derived from both novel and established biotechnologies. Special issues are produced to reflect topics of particular international interest and concern.Three types of papers are welcome: original research reports, short papers, and review articles. The journal will also publish comments and letters to the editor, book reviews, meeting reports and information on regulatory issues. Research Areas Include Areas relevant to biologicals for human and veterinary use such as: • Bacterial vaccines • Blood products • Cell biology • Cell culture technology • Cellular immunology • Cytokines and allied mediators • Diagnostics • Downstream processing • Gene transfer and expression • General bacterology • General virology, endogenous and adventitious viruses • Hormones • Immunochemistry • Molecular biology • Monoclonal antibodies • Parasitology • Prion and prion disease • Protein chemistry • Toxins • Toxoids • Viral vaccines
Biologicals

Cancer Pathogenesis and Therapy

  • ISSN: 2949-7132
Cancer Pathogenesis and Therapy (CPT) is an international open access journal covering key topics in all aspects of cancer research, focusing on mechanism innovation, emerging interdisciplinary and clinical trials research in Oncology. As a Chinese Medical Association (CMA) journal, it strives to publish the highest quality content that provides authoritative guidance to oncology specialists, physicians and researchers. CPT is dedicated to publishing innovative and significant research results in basic research, translation research and clinical oncology, including novel antitumor drugs, especially clinical trials, early screening/prevention, precise diagnosis and targeted therapy, interdisciplinary oncology innovation research and clinical translation in genetics, bioinformatics, pharmacology, and biology, and also new viewpoints, new ideas, new methods and new models of cancer prevention and public health policy. CPT regularly features news and expert interviews to promote expert oncologists' views on oncology guidelines, consensus , and education. CPT is concerned about, but not limited to, the following academic scopes: Basic Cancer Research, Clinical Cancer Research, Cancer prevention and public health policy, Oncological Pharmacology, Cancer Genomics, Cancer Informatics, Drug discovery, Artificial Intelligence, etc. The article types for CPT include: Research articles, Review article, Evidence-based Oncology, Clinical Trial, Editorial, Guideline and Consensus, Study Protocols, Mini review, Perspective, Case report, technical notes, Clinical Image, Letter to Editor, etc. P-ISSN 2097-2563
Cancer Pathogenesis and Therapy

Cell

  • ISSN: 0092-8674
  • 5 Year impact factor: 57.5
  • Impact factor: 64.5
Cell publishes findings of unusual significance in any area of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics. The basic criterion for considering papers is whether the results provide significant conceptual advances into, or raise provocative questions and hypotheses regarding, an interesting and important biological question. In addition to primary research articles in four formats, Cell features review and opinion articles on recent research advances and issues of interest to its broad readership in the leading edge section. Visit the Cell Press website for more information about Cell - http://www.cell.com/cell/home
Cell

Cell Insight

  • ISSN: 2772-8927
Cell Insight is an international, peer-reviewed open-access journal that publishes cutting-edge research articles, letters and reviews on biomedical sciences. The mission of Cell Insight is to provide a fast and expert peer review process to authors and to accelerate communications of researchers for their discoveries in the biological and biomedical fields. The primary criterion for considering manuscripts is whether the studies provide advances into answering important questions relevant to biological and biomedical sciences. Research areas include but are not limited to: Cell biology Immunology Microbiology Cancer biology Neuroscience Genetics Metabolism Disease mechanisms New technology related to biomedical research Translational research Cell Insight is published by Elsevier in partnership with Wuhan University, one of the most comprehensive research universities in China. Led by a team of distinguished scientists, Cell Insight creates a platform of a professional review process and a fast publication process with high quality standards to accelerate scientific communications.
Cell Insight

Cell Reports Methods

  • ISSN: 2667-2375
  • 5 Year impact factor: 3.8
  • Impact factor: 3.8
Cell Reports Methods is an open access, multidisciplinary journal from Cell Press publishing significant methodological advances of broad interest. The primary criterion for publication in Cell Reports Methods is a robust, reproducible method that will spur scientific progress. We will also consider papers presenting a new tool or set of reagents that will be of significant utility and interest to the community. Cell Reports Methods publishes shorter, single-point stories, called Reports, in addition to a longer Article format. Areas of interest include innovations in sequencing and imaging technologies, genome editing, single-molecule approaches, computational methods, biotechnology, and synthetic biology. We are committed to open science and scientific reproducibility. To promote these goals, we offer the following to our authors, reviewers, and readers: Opportunity to co-publish bench-top protocols through collaboration with STAR Protocols Application of the STAR Methods structure to ensure transparency and reproducibility Data and code required for reviewers at the time of submission Mandatory deposition of raw data at resubmission Visit the Cell Press website for more information about Cell Reports Methods - http://www.cell.com/cell-reports-methods/home
Cell Reports Methods